Skip to main content
SpringerLink
Log in

Current treatment options for HBV infection

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Although the increase in agents approved for treating chronic hepatitis B has expanded the therapeutic options for clinicians treating such patients, it also has made selecting the most appropriate agent in a particular clinical setting significantly more confusing. This review critiques the most recent data regarding the treatment options in different subsets of patients with chronic hepatitis B virus (ie, those with chronic hepatitis B, inactive hepatitis B surface antigen carriers, cirrhotics, patients with drug-resistant mutations) and proposes a therapeutic algorithm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. de Franchis R, Hadengue A, Lau G, et al.: EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003, 39(Suppl 1):S3–S25.

    PubMed  Google Scholar 

  2. Hadziyannis SJ: New developments in the treatment of chronic hepatitis B. Expert Opin Biol Ther 2006, 6:913–921.

    Article  PubMed  CAS  Google Scholar 

  3. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507–539.

    Article  PubMed  CAS  Google Scholar 

  4. Keeffe EB, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936–962.

    Article  PubMed  CAS  Google Scholar 

  5. Osborn MK, Lok AS: Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006, 57:1030–1034.

    Article  PubMed  CAS  Google Scholar 

  6. Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123–129.

    Article  PubMed  CAS  Google Scholar 

  7. Lau GK, Piratvisuth T, Luo KX, et al.: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682–2695.

    Article  PubMed  CAS  Google Scholar 

  8. Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011–1020.

    Article  PubMed  CAS  Google Scholar 

  9. Marcellin P, Chang TT, Lim SL, et al.: Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Hepatology 2008, 48:750–758.

    Article  PubMed  CAS  Google Scholar 

  10. Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437–1444.

    Article  PubMed  CAS  Google Scholar 

  11. Han S, Chang T, Chao Y et al.: Four-year entecavir treatment in nucleoside-naive HBeAg (+) patients: results from studies ETV-022 and -901 [abstract]. Hepatology 2007, 46(Suppl 1):654A.

    Google Scholar 

  12. Lai CL, Gane E, Hsu C, et al.: Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006, 44(Suppl 1):222A.

    Google Scholar 

  13. Heathcote J, George J, Gordon S, et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J Hepatol 2008, 48(Suppl 2):S32.

    Article  Google Scholar 

  14. Colonno RJ, Rose RF, Pokornowski K et al.: Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007, 46(Suppl 1):S294.

    Article  Google Scholar 

  15. Lampertico P, Del Ninno E, Vigano M, et al.: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37:756–763.

    Article  PubMed  CAS  Google Scholar 

  16. Manesis EK, Hadziyannis SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001, 121:101–109.

    Article  PubMed  CAS  Google Scholar 

  17. Marcellin P, Piratvisuth T, Brunetto M, et al.: Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40 KD) with or without lamivudine: results of 4-year follow-up. J Hepatol 2008, 48(Suppl 2):S46.

    Article  Google Scholar 

  18. Schiff E, Simsek H, Lee WM, et al.: Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008 [Epub ahead of print].

  19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743–1751.

    Article  PubMed  CAS  Google Scholar 

  20. Marcellin P, Jacobson I, Habersetzer F, et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 2008, 48(Suppl 2):S26.

    Article  Google Scholar 

  21. Buti M, Hadziyannis SJ, Mathurin P, et al.: Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis. J Hepatol 2008, 48(Suppl 2):S33.

    Article  Google Scholar 

  22. Chu CM, Liaw YF: Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006, 26:142–152.

    Article  PubMed  CAS  Google Scholar 

  23. Liaw YF, Sung JJ, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521–1531.

    Article  PubMed  CAS  Google Scholar 

  24. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y: Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008, 6:268–274.

    Article  PubMed  CAS  Google Scholar 

  25. Lok AS, Zoulim F, Locarnini S, et al.: Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254–265.

    Article  PubMed  CAS  Google Scholar 

  26. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45:307–313.

    Article  PubMed  CAS  Google Scholar 

  27. Manns M, Jeffers L, Dalekos G et al.: The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM experienced subjects treated for chronic hepatitis B (CHB). J Hepatol 2008, 48(Suppl 2):S33.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 115 26, Athens, Greece

    Stephanos J. Hadziyannis

Authors
  1. Dimitrios Vassilopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanos J. Hadziyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanos J. Hadziyannis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vassilopoulos, D., Hadziyannis, S.J. Current treatment options for HBV infection. Curr hepatitis rep 8, 26–30 (2009). https://doi.org/10.1007/s11901-009-0004-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-009-0004-z

Keywords

Search

Navigation